Archive for the 'Irritable Bowel Syndrome' Category
Constipated? New Drug Linaclotide May Bring Serious Relief Home
In a new study funded by Ironwood Pharmaceuticals, an experimental drug called linaclotide can help reduce the symptoms of chronic constipation, which may serve as a serious relief for many. In reality, it affects nearly 30 million Americans and costs more than $1 billion annually to evaluate and treat…
Original post by Six Until Me.
No commentsLexicon’s IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it has successfully completed a Phase 1 clinical trial of LX1033, an orally-delivered small molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d)…
Original post by Six Until Me.
No commentsFDA Grants Fast Track Designation To Tioga Pharmaceuticals’ Asimadoline For The Treatment Of Diarrhea-Predominant Irritable Bowel Syndrome
Tioga Pharmaceuticals, Inc. announced that its investigational compound asimadoline has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with diarrhea-predominant irritable bowel syndrome (D-IBS)…
Original post by Lemonade Life
No commentsCedars-Sinai Research Deepens Understanding Of Most Common Gastrointestinal Disorder In U.S., Linking It To Bacterial Overgrowth, Food Poisoning
Cedars-Sinai researchers have reported two advances in the understanding of Irritable Bowel Syndrome, the most common gastrointestinal disorder in the United States, affecting an estimated 30 million people. One study provides further evidence that IBS is linked to an overgrowth of bacteria in the gut…
Original post by Six Until Me.
No comments2011 Digestive Disease Week: UNC Research Highlights
Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery…
Original post by Six Until Me.
No commentsScientists Unmask Mysterious Cells As Key ‘Border Patrol Agents’ In The Intestine
Researchers at UT Southwestern Medical Center have uncovered new clues about how the intestine maintains friendly relations with the 100 trillion symbiotic bacteria that normally live in the digestive tract…
Original post by Six Until Me.
No commentsIronwood And Forest To Present Linaclotide Results From Phase 3 Trials In Patients With Irritable Bowel Syndrome With Constipation
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be presenting linaclotide results from Phase 3 clinical trials in patients with irritable bowel syndrome with constipation (IBS-C) during the 2011 Digestive Disease Week (DDW) annual meeting that will be held in Chicago from May 7 through May 10, 2011…
Original post by Better Health
No commentsC. Difficile Increases Risk Of Death Sixfold In Patients With Inflammatory Bowel Disease
Patients admitted to hospital with inflammatory bowel disease (IBD) face a sixfold greater risk of death if they become infected with Clostridium difficile, a new study has found. The researchers say IBD patients should be screened on admission to protect them from serious illness…
Original post by Pharmalot
No commentsPeppermint Earns Respect In Mainstream Medicine
University of Adelaide researchers have shown for the first time how peppermint helps to relieve Irritable Bowel Syndrome, which affects up to 20% of the population…
Original post by Pharmalot
No commentsSalix Receives Anticipated FDA Complete Response Letter On XIFAXAN(R) 550 Mg Tablets Non-C IBS Supplemental New Drug Application
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on March 7, 2011 for the supplemental New Drug Application (sNDA) for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating…
Original post by Diabetes Daily
No comments